The Efficacy and Safety of Teplizumab in the Treatment of Stage 3 Type 1 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Diabetes Metab Syndr Obes · 2026 · PMC13217445 · PMID 42221148

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

Teplizumab improved C-peptide AUC preservation at 9–15 months (SMD=0.28, 95% CI 0.09–0.48, P=0.016; exceeded MCID 0.20), and showed only a favorable trend at 18–24 months (SMD=0.27, 95% CI −0.02–0.56).

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.